ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo explore the therapeutic mechanism of
methodsMale BALB/c mice bearing subcutaneous colorectal cancer CT26 cell xenografts were randomized into control group, model group, and treatment group. The mice in model and treatment groups were given intraperitoneal 5-FU injections every 3 days and treated with daily gavage of saline and QFG for 21 days, respectively; the mice in the control group and normally fed mice were given only saline gavage. Gripping test and hanging test of the mice were performed before and after the treatment, and on day 21, tumor weight and gastrocnemius muscle weight were measured, and histopathology and cell apoptosis in the gastrocnemius muscle were examined with HE staining, transmission electron microscopy and TUNEL assay. ATP content in the muscle was measured, and protein expressions of AMPK, PGC-1α, Cyt c, AIF, Apaf-1, Smac, Bcl-2, Bax, cleaved caspase-3 and cleaved caspase-9 were determined with immunohistochemistry.
resultsThe tumor-bearing mice in the control group showed significantly decreased gastrocnemius muscle weight and grip and suspension test scores. The gastrocnemius muscle showed ultrastructure injuries with lowered ATP content, obvious cell apoptosis, decreased expressions of AMPK, PGC-1 α, and Bcl-2, and increased expressions of Bax, Cyto C, AIF, Apaf-1, Smac, cleaved caspase-3 and cleaved caspase-9. These changes were obviously worsened in 5-FU-treated mice, while QFG treatment significantly increased gastrocnemius muscle weight and strength, ameliorated its ultrastructural injuries, reduced cell apoptosis, and reversed the abnormal protein expressions.
conclusionsQFG alleviates 5-FU-induced skeletal muscle fatigue in tumor-bearing mice by activating the AMPK/PGC-1α pathway and inhibiting mitochondria-dependent apoptosis in the gastrocnemius muscle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.